Author:
Dempke Wolfram C. M.,Desole Maximilian,Chiusolo Patrizia,Sica Simona,Schmidt-Hieber Martin
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference46 articles.
1. Banday S, Faroog Z, Ganai SA, Altaf M (2020) Therapeutic strategies against hDOT1L as a potential drug target in MLL-arranged leukemias. Clin Epigenet 12:73
2. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOTL1. Cancer Cell 20:66–78
3. Burrows F, Wu T, Kessler L, Shuangwei L, Zhang J, Zarrinkar P et al (2017) A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML. Mol Targets Cancer Ther 17(Suppl 1):abstract LB-A27
4. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701). A randomized, open-label, phase 3 study. Lancet 379:1508–1516
5. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A (2006) The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA 103:1018–1023
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献